RÉSUMÉ
Newly synthesized vaccines prepared from formalin-killed bacteria Streptococcus pyogenes were investigated in the current study to evaluate the effectiveness of the newly synthesized vaccine as well as their safety by injected intraperitoneal. The study involved several steps 1st step is the preparation of the vaccine followed by the 2nd step: Evaluate the effectiveness and vaccine safety against pathogenic S. pyogenes through 4 different groups including control (Group I). Group II (Bacterial, infected group), Group III (Vaccine), and the Last group was the challenged group after the vaccination (Vacc + Bac). Different Immunological and biochemical parameters were measured in addition to hematological and histopathological examinations. For example, oxidative/antioxidants, inflammatory biomarkers, fragmentation and cell damage, and finally the histopathological study. The current study showed an increase in all oxidative, inflammatory, and cell damage (DNA fragmentation assays), additionally markedly elevation in histopathological cell damage in the infected group (Group II) compared with the control group. The vaccine and challenged after vaccination group (vaccine + Bacteria), showed great improvement in oxidative biomarkers (LPO) and an increase in antioxidants biomarkers (GSH, SOD, GST, DPPH, ABTS, GR and GPx), Also the inflammation and histopathological examination. The newly synthesized vaccine improved the resistance of Oreochromis niloticus and can be used as a preventive therapy agent for pathogenic bacteria S. pyogenes.
Sujet(s)
Cichlides , Foie , Infections à streptocoques , Vaccins antistreptococciques , Streptococcus pyogenes , Vaccination , Animaux , Streptococcus pyogenes/immunologie , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/immunologie , Cichlides/immunologie , Cichlides/microbiologie , Foie/microbiologie , Foie/anatomopathologie , Foie/métabolisme , Vaccination/méthodes , Vaccins antistreptococciques/immunologie , Formaldéhyde , Vaccins inactivés/immunologie , Maladies des poissons/prévention et contrôle , Maladies des poissons/microbiologie , Maladies des poissons/immunologie , Antioxydants/pharmacologie , Stress oxydatif/effets des médicaments et des substances chimiques , Marqueurs biologiquesRÉSUMÉ
Tilapia is one of the most important farmed fish in the world and the most cultivated in Brazil. The increase of this farming favors the appearance of diseases, including bacterial diseases. Therefore, the aim of this study was to evaluate the bactericidal activity of copaiba oil, Copaifera duckei, against Streptococcus agalactiae and Flavobacterium columnare and the dietary effect of copaiba oil on zootechnical performance, hematological, biochemical, immunological, and histological analysis before and after an intraperitoneal infection (body cavity) with S. agalactiae in Nile tilapia. For this, fish were randomly distributed into 15 fiber tanks in five treatments (0, 0.25, 0.50, 0.75, and 1.0%) and fed with a commercial diet supplemented with copaiba oil for 30 days. After this period, the fish were randomly redistributed for the experimental challenge with S. agalactiae into six treatments (T0, T1, T2, T3, T4, and T5), the fish were anesthetized, and blood samples were collected to assess hematological, biochemical, immunological, and histological parameters. Copaiba oil showed bactericidal activity against Streptococcus spp. and Flavobacterium spp. in vitro. In addition, concentrations of 0.75 and 1.0% of copaiba oil have an anti-inflammatory effect and improve hematological and immunological parameters, increasing leukocyte numbers, albumin, and serum lytic activity. Furthermore, there is an increase in the intestinal villus length and tissue damage in groups at concentrations of 0.75 and 1.0% of copaiba oil. In conclusion, copaiba oil presented bactericidal activity against Streptococcus spp. and Flavobacterium spp. in vitro, and oral supplementation at concentrations of 0.75 and 1.0% compared to the control group enhanced non-specific immune parameters and digestibility in Nile Tilapia.
Sujet(s)
Cichlides , Compléments alimentaires , Maladies des poissons , Flavobacterium , Streptococcus agalactiae , Animaux , Streptococcus agalactiae/effets des médicaments et des substances chimiques , Flavobacterium/effets des médicaments et des substances chimiques , Maladies des poissons/microbiologie , Maladies des poissons/traitement médicamenteux , Maladies des poissons/prévention et contrôle , Fabaceae/composition chimique , Antibactériens/pharmacologie , Infections à streptocoques/médecine vétérinaire , Infections à streptocoques/traitement médicamenteux , Infections à streptocoques/prévention et contrôle , Huiles végétales/pharmacologie , Infections à Flavobacteriaceae/médecine vétérinaire , Infections à Flavobacteriaceae/microbiologie , Infections à Flavobacteriaceae/traitement médicamenteux , Infections à Flavobacteriaceae/prévention et contrôle , Aliment pour animaux , Administration par voie orale , Aquaculture/méthodesRÉSUMÉ
Intraamniotic inflammation and infection complicate 2% to 5% of term deliveries. Group B Streptococcus (GBS) is a common cause of intraamniotic infection associated with invasive neonatal disease and maternal morbidity. Universal vaginal-rectal screening for GBS colonization is recommended between 36 and 37 weeks. Intrapartum antibiotic prophylaxis is recommended for individuals with positive GBS screens and other risk factors. Intravenous penicillin is the preferred antimicrobial agent. Individuals with penicillin allergies may receive cefazolin for low-risk allergies and either clindamycin or vancomycin for high-risk allergies, depending on their antimicrobial susceptibilities. Clinical trials are underway to evaluate the safety and immunogenicity of maternal anti-GBS vaccine candidates.
Sujet(s)
Antibactériens , Antibioprophylaxie , Chorioamnionite , Complications infectieuses de la grossesse , Infections à streptocoques , Streptococcus agalactiae , Humains , Grossesse , Infections à streptocoques/diagnostic , Infections à streptocoques/traitement médicamenteux , Infections à streptocoques/prévention et contrôle , Femelle , Antibioprophylaxie/méthodes , Complications infectieuses de la grossesse/traitement médicamenteux , Complications infectieuses de la grossesse/microbiologie , Complications infectieuses de la grossesse/prévention et contrôle , Antibactériens/usage thérapeutique , Chorioamnionite/microbiologie , Chorioamnionite/traitement médicamenteux , Vaccins antistreptococciques , Nouveau-néRÉSUMÉ
Group B Streptococcus (GBS) is the leading cause of bacterial neonatal sepsis. This study aimed to confirm the effect of Ligilactobacillus salivarius V4II-90 on GBS colonisation during pregnancy. A randomised, multicentre, double-blind, placebo-controlled, parallel-group study was conducted in seven hospitals in Madrid, Spain. The sample was broken down into two groups with 20 participants each (n = 40) in order to show reduced GBS colonisation frequency in the probiotic versus the placebo group. Pregnant participants positive for vaginal-rectal colonisation before or during the 13th week of gestation were randomly assigned to either the placebo or the probiotic group. The probiotic, L. salivarius V4II-90 at 1 × 109 cfu/day was administered for 12 weeks, starting at week 21-23 of gestation. The primary outcome was the percentage of participants with vaginal and/or rectal GBS colonisation at the end of the intervention period (35 weeks of gestation). Secondary outcomes were changes in the microbial composition of vaginal and rectal exudates; premature delivery; premature rupture of membranes; intrapartum antibiotics; new-borns with early or late-onset GBS sepsis; adverse events (AEs); and GBS test results performed at the hospital at week 35 of gestation. Of the 481 participants included, 44 were vaginal-rectal colonised with GBS and randomised. 43 completed the study (20 in the probiotic group and 23 in the placebo group). After intervention, GBS was eradicated in six participants (27%) from the placebo group and in twelve participants (63%) from the probiotic group ( P = 0.030). None of the 185 AEs reported were identified as possibly, probably, or definitely related to the investigational product. In conclusion, oral administration of L. salivarius V4II-90 is a safe and successful strategy to significantly decrease the rates of GBS colonisation at the end of pregnancy and, therefore, to reduce the exposure of subjects and their infants to intrapartum antibiotic prophylaxis. Trial registered at ClinicalTrials.gov: number NCT03669094.
Sujet(s)
Ligilactobacillus salivarius , Complications infectieuses de la grossesse , Probiotiques , Rectum , Infections à streptocoques , Streptococcus agalactiae , Vagin , Humains , Femelle , Grossesse , Probiotiques/administration et posologie , Méthode en double aveugle , Streptococcus agalactiae/croissance et développement , Streptococcus agalactiae/effets des médicaments et des substances chimiques , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/microbiologie , Infections à streptocoques/traitement médicamenteux , Adulte , Vagin/microbiologie , Rectum/microbiologie , Ligilactobacillus salivarius/physiologie , Complications infectieuses de la grossesse/microbiologie , Complications infectieuses de la grossesse/prévention et contrôle , Complications infectieuses de la grossesse/traitement médicamenteux , Nouveau-né , Espagne , Jeune adulteRÉSUMÉ
Group B Streptococcus (GBS) disease in neonates occurs in two forms: early-onset disease (EOD), (day 0-6), and late-onset disease (LOD), (day 7-90). This review investigates that risk-based intrapartum screening and antibiotics have reduced the incidence of EOD, but not LOD, in Denmark. No clinical or laboratory tests can rule out GBS disease at symptom onset. Thus, a high proportion of uninfected infants receive antibiotics, although this varies widely, and may be reduced by strategies of antibiotic stewardship. A future GBS vaccine for pregnant women may potentially reduce disease burden and antibiotic exposure.
Sujet(s)
Antibactériens , Infections à streptocoques , Streptococcus agalactiae , Humains , Infections à streptocoques/diagnostic , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/traitement médicamenteux , Nouveau-né , Streptococcus agalactiae/isolement et purification , Antibactériens/usage thérapeutique , Antibactériens/administration et posologie , Femelle , Grossesse , Danemark/épidémiologie , Complications infectieuses de la grossesse/diagnostic , Complications infectieuses de la grossesse/microbiologie , Complications infectieuses de la grossesse/prévention et contrôle , Complications infectieuses de la grossesse/traitement médicamenteux , Nourrisson , Vaccins antistreptococciques/administration et posologie , Transmission verticale de maladie infectieuse/prévention et contrôleRÉSUMÉ
BACKGROUND: Maternal Group B Streptococcus (GBS) colonization is influenced by many factors but results are inconsistent. Consideration of antenatal risk factors may help inform decision making on GBS microbiological culture screening where universal screening is not standard of care. We sought to identify independent predictors of GBS colonization at 34-37 weeks gestation incorporating vaginal symptoms, perineal hygiene measures, sexual activity, and a potential novel factor, constipation. METHODS: In this prospective cross-sectional study, 573 women at 34-37 weeks gestation had an ano-vaginal swab taken and sent for selective culture for GBS. Women were asked about vaginal bleeding, discharge, irritation and candidiasis, antibiotic use during pregnancy, ano-vaginal hygiene practices such as douching and perineal cleansing after toileting, sexual intercourse related activities, and a potential novel factor for GBS carriage, constipation. Maternal basic demographics and obstetric-related characteristics were also collected. Bivariate analyses were performed to identify associates of GBS colonization. All variables with p < 0.05 found on bivariate analysis were then included into a model for multivariable binary logistic regression analysis to identify independent risk factors for GBS colonization. RESULTS: GBS colonization was found in 235/573 (41.0%) of participants. Twenty six independent variables were considered for bivariate analysis. Eight were found to have p < 0.05. Following adjusted analysis, six independent predictors of GBS colonization were identified: ethnicity, previous neonatal GBS prophylaxis, antenatal vaginal irritation, antibiotic use, recent panty liner use, and frequency of sexual intercourse. Vaginal discharge and perineal cleansing were not associated after adjustment. Recent douching and constipation were not associated on bivariate analysis. CONCLUSION: The identification of independent predictors of GBS colonization in late pregnancy may inform the woman and care provider in their shared decision making for microbiological screening at 35-38 weeks gestation in locations where universal GBS screening is not standard of care. ETHICS OVERSIGHT: This study was approved by the Medical Ethics Committee of University Malaya Medical Centre (UMMC) on August 9, 2022, reference number 2022328-11120.
Sujet(s)
Constipation , Hygiène , Périnée , Complications infectieuses de la grossesse , Comportement sexuel , Infections à streptocoques , Streptococcus agalactiae , Vagin , Humains , Femelle , Grossesse , Études prospectives , Streptococcus agalactiae/isolement et purification , Adulte , Constipation/microbiologie , Constipation/prévention et contrôle , Vagin/microbiologie , Études transversales , Complications infectieuses de la grossesse/microbiologie , Complications infectieuses de la grossesse/prévention et contrôle , Complications infectieuses de la grossesse/diagnostic , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/diagnostic , Périnée/microbiologie , Périnée/traumatismes , Facteurs de risque , Canal anal/microbiologie , Troisième trimestre de grossesseRÉSUMÉ
Streptococcus agalactiae, also known as Group B Streptococcus (GBS), is a predominant pathogen of neonatal sepsis, commonly associated with early-onset neonatal sepsis. GBS has also been associated with cases of late-onset sepsis potentially originating from the intestine. Previous findings have shown GBS can colonize the infant intestinal tract as part of the neonatal microbiota. To better understand GBS colonization dynamics in the neonatal intestine, we collected stool and milk samples from prematurely born neonates for identification of potential pathogens in the neonatal intestinal microbiota. GBS was present in approximately 10% of the cohort, and this colonization was not associated with maternal GBS status, delivery route, or gestational weight. Interestingly, we observed the relative abundance of GBS in the infant stool negatively correlated with maternal IgA concentration in matched maternal milk samples. Using a preclinical murine model of GBS infection, we report that both vertical transmission and direct oral introduction resulted in intestinal colonization of GBS; however, translocation beyond the intestine was limited. Finally, vaccination of dams prior to breeding induced strong immunoglobulin responses, including IgA responses, which were associated with reduced mortality and GBS intestinal colonization. Taken together, we show that maternal IgA may contribute to infant immunity by limiting the colonization of GBS in the intestine.
Sujet(s)
Translocation bactérienne , Immunoglobuline A , Infections à streptocoques , Streptococcus agalactiae , Streptococcus agalactiae/croissance et développement , Streptococcus agalactiae/immunologie , Animaux , Infections à streptocoques/microbiologie , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/immunologie , Femelle , Nouveau-né , Humains , Souris , Transmission verticale de maladie infectieuse , Fèces/microbiologie , Intestins/microbiologie , Intestins/immunologie , Lait humain/microbiologie , Microbiome gastro-intestinal , Grossesse , Anticorps antibactériens/sang , Anticorps antibactériens/immunologie , Modèles animaux de maladie humaine , Souris de lignée C57BL , MâleRÉSUMÉ
A maternal vaccine to protect newborns against invasive Streptococcus agalactiae infection is a developing medical need. The vaccine should be offered during the third trimester of pregnancy and induce strong immune responses and placental transfer of protective antibodies. Polysaccharide vaccines against S. agalactiae conjugated to protein carriers are in advanced stages of development. Additionally, protein-based vaccines are also in development, showing great promise as they can provide protection regardless of serotype. Furthermore, safety concerns regarding a new vaccine are the main barriers identified. Here, we present vaccines in development and identified safety, cost, and efficacy concerns, especially in high-need, low-income countries.
Sujet(s)
Infections à streptocoques , Vaccins antistreptococciques , Streptococcus agalactiae , Streptococcus agalactiae/immunologie , Humains , Infections à streptocoques/immunologie , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/microbiologie , Vaccins antistreptococciques/immunologie , Grossesse , Femelle , Animaux , Complications infectieuses de la grossesse/immunologie , Complications infectieuses de la grossesse/prévention et contrôle , Complications infectieuses de la grossesse/microbiologie , Développement de vaccin , Nouveau-né , Anticorps antibactériens/immunologieRÉSUMÉ
Streptococcus suis is one of the major pathogens of pigs circulating worldwide, and the development of vaccines will help to effectively control streptococcosis in swine. In this study, we evaluated the potential of three membrane associated proteins, histidine kinase (HK), glycosyltransferase family 2 (Gtf-2) and phosphate binding protein (PsbP) of S. suis as subunit vaccines. Bioinformatics analysis shows that protein ABC is highly conserved in S. suis. To verify the protective effects of these proteins in animal models, recombinant protein HK, Gtf-2 and PsbP were used to immunize BALB/c mice separately. The results showed that these proteins immunization in mice can effectively induce strong humoral immune responses, protect mice from cytokine storms caused by S. suis infection, and have a significant protective effect against lethal doses of S. suis infection. Furthermore, antibodies with opsonic activity exist in the recombinant proteins antiserum to assist phagocytic cells in killing S. suis. Overall, these results indicated that these recombinant proteins all elicit good immune protective effect against S. suis infection and can be represent promising candidate antigens for subunit vaccines against S. suis.
Sujet(s)
Anticorps antibactériens , Protéines bactériennes , Modèles animaux de maladie humaine , Souris de lignée BALB C , Protéines recombinantes , Infections à streptocoques , Vaccins antistreptococciques , Streptococcus suis , Vaccins sous-unitaires , Streptococcus suis/immunologie , Streptococcus suis/génétique , Animaux , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/immunologie , Infections à streptocoques/microbiologie , Souris , Anticorps antibactériens/sang , Anticorps antibactériens/immunologie , Protéines bactériennes/immunologie , Protéines bactériennes/génétique , Vaccins sous-unitaires/immunologie , Vaccins sous-unitaires/génétique , Protéines recombinantes/immunologie , Protéines recombinantes/génétique , Vaccins antistreptococciques/immunologie , Vaccins antistreptococciques/administration et posologie , Vaccins antistreptococciques/génétique , Sérogroupe , Cytokines/métabolisme , Femelle , Protéines membranaires/immunologie , Protéines membranaires/génétique , Immunité humorale , Antigènes bactériens/immunologie , Antigènes bactériens/génétique , Maladies des porcs/prévention et contrôle , Maladies des porcs/immunologie , Maladies des porcs/microbiologie , Suidae , Biologie informatiqueRÉSUMÉ
Group B Streptococcus (GBS) is a frequent colonizer of the human genital and gastrointestinal tract. In pregnant or postpartum persons, colonization is often asymptomatic and can contribute to infectious morbidity in both the parturient and the newborn. The prevalence of invasive GBS disease has dramatically decreased over the past 3 decades. However, despite standardized clinical algorithms, GBS disease remains a public health concern. Our review summarizes the GBS bacteria pathophysiology, morbidity, management guidelines, and summarizes ongoing research. While novel testing and parturient vaccination are being explored, barriers exist, preventing guideline updates and widespread implementation.
Sujet(s)
Complications infectieuses de la grossesse , Infections à streptocoques , Streptococcus agalactiae , Humains , Femelle , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/diagnostic , Grossesse , Complications infectieuses de la grossesse/prévention et contrôle , Complications infectieuses de la grossesse/diagnostic , Complications infectieuses de la grossesse/microbiologie , Transmission verticale de maladie infectieuse/prévention et contrôle , Nouveau-né , Vaccins antistreptococciques , Antibactériens/usage thérapeutiqueRÉSUMÉ
Streptococcus suis is a bacterial pathogen that can cause significant economic losses in the swine industry due to high morbidity and mortality rates in infected animals. Vaccination with bacterins, which consist of inactivated bacteria and adjuvants to enhance the pig's immune response, is an effective approach to control S. suis infections in piglets. Here we provide a description of S. suis bacterins and the methods for vaccine preparation. Moreover, this chapter also describes the addition of recombinant Sao (rSao-L) protein to the S. suis bacterin, aiming to enhance the efficacy of the bacterins against S. suis in piglets. Furthermore, the methods for evaluating the immune response elicited by the bacterins are also covered in this chapter.
Sujet(s)
Streptococcus suis , Animaux , Suidae , Streptococcus suis/immunologie , Infections à streptocoques/immunologie , Infections à streptocoques/microbiologie , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/médecine vétérinaire , Maladies des porcs/microbiologie , Maladies des porcs/prévention et contrôle , Maladies des porcs/immunologie , Vaccination/méthodes , Vaccins antibactériens/immunologie , Adjuvants immunologiques/pharmacologie , Anticorps antibactériens/immunologie , Protéines recombinantes/immunologie , Protéines recombinantes/génétique , Vaccins antistreptococciques/immunologie , Vaccins antistreptococciques/administration et posologieRÉSUMÉ
In response to the global threat posed by bacterial pathogens, which are the second leading cause of death worldwide, vaccine development is challenged by the diversity of bacterial serotypes and the lack of immunoprotection across serotypes. To address this, we introduce BacScan, a novel genome-wide technology for the rapid discovery of conserved highly immunogenic proteins (HIPs) across serotypes. Using bacterial-specific serum, BacScan combines phage display, immunoprecipitation, and next-generation sequencing to comprehensively identify all the HIPs in a single assay, thereby paving the way for the development of universally protective vaccines. Our validation of this technique with Streptococcus suis, a major pathogenic threat, led to the identification of 19 HIPs, eight of which conferred 20-100% protection against S. suis challenge in animal models. Remarkably, HIP 8455 induced complete immunity, making it an exemplary vaccine target. BacScan's adaptability to any bacterial pathogen positions it as a revolutionary tool that can expedite the development of vaccines with broad efficacy, thus playing a critical role in curbing bacterial transmission and slowing the march of antimicrobial resistance.
Sujet(s)
Protéines bactériennes , Animaux , Souris , Protéines bactériennes/immunologie , Protéines bactériennes/génétique , Infections à streptocoques/immunologie , Infections à streptocoques/prévention et contrôle , Streptococcus suis/immunologie , Streptococcus suis/génétique , Génome bactérien , Séquençage nucléotidique à haut débit , Femelle , Antigènes bactériens/immunologie , Antigènes bactériens/génétique , Humains , Vaccins antibactériens/immunologieRÉSUMÉ
Strangles is a highly contagious disease of the equine upper respiratory tract caused by Streptococcus equi subspecies. Streptococcus equi subsp. equi (S. equi) and Streptococcus equi subsp. zooepidemicus (S. zooepidemicus) was isolated, as local, hot, and field strains, from horses clinically suffering from respiratory distress. The isolated Streptococci were identified using bacteriological and molecular techniques. Four formulations of inactivated S. equi vaccines were developed and evaluated. The first formulation was prepared using the S. equi isolates, adjuvanted with MONTANIDE GEL adjuvant, while the second formulation was adjuvanted with MONTANIDE ISA-70 adjuvant. The other 2 formulations were inactivated combined vaccines prepared from both S. equi and S. zooepidemicus isolates. The 3rd formulation was the combined isolates adjuvanted with MONTANIDE GEL while the 4th formulation was the combined isolates adjuvanted with MONTANIDE ISA-70. The developed vaccines' physical properties, purity, sterility, safety, and potency were ensured. The immunizing efficacy was determined in isogenic BALB/c mice and white New Zealand rabbits using the passive hemagglutination test. Also, the antibodies' titer of the combined S. equi and S. zooepidemicus vaccine adjuvanted with MONTANIDE ISA-70 in foals was tracked using an indirect enzyme-linked immunosorbent assay. The protective efficacy of the developed vaccines was determined using a challenge test in both laboratory and field animal models, where a 75% protection rate was achieved. The combined vaccine proved to be more efficacious than the monovalent vaccine. Also, the MONTANIDE ISA-70 adjuvant provided significant protective efficacy than the MONTANIDE GEL. The current work is introducing a very promising mitigative and strategic controlling solution for strangles.
Sujet(s)
Maladies des chevaux , Souris de lignée BALB C , Infections à streptocoques , Vaccins antistreptococciques , Streptococcus equi , Streptococcus , Animaux , Streptococcus equi/immunologie , Equus caballus , Lapins , Infections à streptocoques/médecine vétérinaire , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/microbiologie , Infections à streptocoques/immunologie , Souris , Maladies des chevaux/prévention et contrôle , Maladies des chevaux/microbiologie , Maladies des chevaux/immunologie , Vaccins antistreptococciques/immunologie , Vaccins antistreptococciques/administration et posologie , Femelle , Anticorps antibactériens/sang , Adjuvants immunologiques/administration et posologie , Vaccins inactivés/immunologieRÉSUMÉ
Streptococcus suis is a bacterial pathogen that causes important economic losses to the swine industry worldwide. Since there are no current commercial vaccines, the use of autogenous vaccines applied to gilts/sows to enhance transfer of passive immunity is an attractive alternative to protect weaned piglets. However, there is no universal standardization in the production of autogenous vaccines and the vaccine formulation may be highly different among licenced manufacturing laboratories. In the present study, an autogenous vaccine that included S. suis serotypes 2, 1/2, 5, 7 and 14 was prepared by a licensed laboratory and administrated to gilts using a three-dose program prior to farrowing. The antibody response in gilts as well as the passive transfer of antibodies to piglets was then evaluated. In divergence with previously published data with an autogenous vaccine produced by a different company, the increased response seen in gilts was sufficient to improve maternal antibody transfer to piglets up to 5 weeks of age. However, piglets would still remain susceptible to S. suis disease which often appears during the second part of the nursery period. Vaccination did not affect the shedding of S. suis (as well as that of the specific S. suis serotypes included in the vaccine) by either gilts or piglets. Although all antibiotic treatments were absent during the trial, the clinical protective effect of the vaccination program with the autogenous vaccine could not be evaluated, since limited S. suis cases were present during the trial, confirming the need for a complete evaluation of the clinical protection that must include laboratory confirmation of the aetiological agent involved in the presence of S. suis-associated clinical signs. Further studies to evaluate the usefulness of gilt/sow vaccination with autogenous vaccines to protect nursery piglets should be done.
Sujet(s)
Autovaccins , Infections à streptocoques , Streptococcus suis , Maladies des porcs , Animaux , Streptococcus suis/immunologie , Suidae , Maladies des porcs/prévention et contrôle , Maladies des porcs/microbiologie , Maladies des porcs/immunologie , Infections à streptocoques/médecine vétérinaire , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/immunologie , Femelle , Immunité acquise d'origine maternelle , Vaccins antistreptococciques/immunologie , Vaccins antistreptococciques/administration et posologie , Sérogroupe , Vaccination/médecine vétérinaireRÉSUMÉ
Dental caries is a prevalent oral disease that mainly results from Streptococcus mutans. Susceptibility to S. mutans decreased rapidly after weaning in a well-known rat model. However, owing to the lack of time to establish protective immunity ahead of challenge, the weaning rat model is suboptimal for assessing prophylactic vaccines against S. mutans infection. In this study, we found that, in adult rats, S. mutans cultured under air-restricted conditions showed dramatically increased colonization efficacy and accelerated development of dental caries compared with those cultured under air-unrestricted conditions. We propose that S. mutans cultured under air-restricted conditions can be used to develop an optimal caries model, especially for the evaluation of prophylactic efficacy against S. mutans. Therefore, we used the anti-caries vaccine, KFD2-rPAc, to reevaluate the protection against the challenge of S. mutans. In immunized rats, rPAc-specific protective antibodies were robustly elicited by KFD2-rPAc before the challenge. In addition to inhibiting the initial and long-term colonization of S. mutans in vivo, KFD2-rPAc immunization showed an 83% inhibitory efficacy against the development of caries, similar to that previously evaluated in a weaning rat model. These results demonstrate that culturing under air-restricted conditions can promote S. mutans infection in adult rats, thereby helping establish a rat infection model to evaluate the prophylactic efficacy of vaccines and anti-caries drugs.
Sujet(s)
Anticorps antibactériens , Caries dentaires , Modèles animaux de maladie humaine , Streptococcus mutans , Animaux , Caries dentaires/prévention et contrôle , Caries dentaires/microbiologie , Caries dentaires/immunologie , Streptococcus mutans/immunologie , Rats , Anticorps antibactériens/immunologie , Anticorps antibactériens/sang , Vaccins antistreptococciques/immunologie , Vaccins antistreptococciques/administration et posologie , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/immunologie , Infections à streptocoques/microbiologie , Femelle , Rat Sprague-DawleyRÉSUMÉ
BACKGROUND: Group B Streptococcus (GBS) is a leading cause of morbidity and mortality in young infants worldwide. This study aimed to investigate candidate GBS vaccine targets, virulence factors, and antimicrobial resistance determinants. METHODS: We used whole-genome sequencing to characterize invasive GBS isolates from infants < 3 months of age obtained from a multicenter population-based study conducted from 2015 to 2021 in China. RESULTS: Overall, seven serotypes were detected from 278 GBS isolates, four (Ia, Ib, III, V) of which accounted for 97.8 %. We detected 30 sequence types (including 10 novel types) that were grouped into six clonal complexes (CCs: CC1, CC10, CC17, CC19, CC23 and CC651); three novel ST groups in CC17 were detected, and the rate of CC17, considered a hyperinvasive neonatal clone complex, was attached to 40.6 % (113/278). A total of 98.9 % (275/278) of isolates harbored at least one alpha-like protein gene. All GBS isolates contained at least one of three pilus backbone determinants and the pilus types PI-2b and PI-1 + PI-2a accounted for 79.8 % of the isolates. The 112 serotype III/CC17 GBS isolates were all positive for hvgA. Most of the isolates (75.2 %) were positive for serine-rich repeat glycoprotein determinants (srr1or srr2). Almost all isolates possessed cfb (99.6 %), c1IE (100 %), lmb (95.3 %) or pavA (100 %) gene. Seventy-seven percent of isolates harboured more than three antimicrobial resistance genes with 28.4 % (79/278) gyrA quinoloneresistancedeterminants mutation, 83.8 % (233/278) carrying tet cluster genes and 77.3 % (215/278) carrying erm genes which mediated fluoroquinolone, tetracycline and clindamycin resistance, respectively." CONCLUSIONS: The findings from this large whole-genome sequence of GBS isolates establish important baseline data required for further surveillance and evaluating the impact of future vaccine candidates.
Sujet(s)
Infections à streptocoques , Vaccins antistreptococciques , Streptococcus agalactiae , Facteurs de virulence , Séquençage du génome entier , Humains , Streptococcus agalactiae/génétique , Streptococcus agalactiae/pathogénicité , Streptococcus agalactiae/effets des médicaments et des substances chimiques , Streptococcus agalactiae/immunologie , Streptococcus agalactiae/isolement et purification , Streptococcus agalactiae/classification , Séquençage du génome entier/méthodes , Facteurs de virulence/génétique , Nourrisson , Infections à streptocoques/microbiologie , Infections à streptocoques/épidémiologie , Infections à streptocoques/prévention et contrôle , Vaccins antistreptococciques/immunologie , Nouveau-né , Chine/épidémiologie , Femelle , Sérogroupe , Mâle , Résistance bactérienne aux médicaments/génétique , Génome bactérien , Antibactériens/pharmacologieRÉSUMÉ
Rheumatic heart disease (RHD) and acute rheumatic fever (ARF) disproportionately affect individuals in low-resource settings. ARF is attributed to an immune response to Group A Streptococcus (GAS) following GAS pharyngitis and potentially GAS impetigo in which infection can be initiated by scabies infestation. The burden of ARF and RHD in Aboriginal and Torres Strait Islander people in Australia is among the highest globally. Following recent calls to include dog management programs in ARF and RHD prevention programs, we believe it is timely to assess the evidence for this, particularly since previous recommendations excluded resources to prevent zoonotic canine scabies. While phylogenetic analyses have suggested that the Sarcoptes mite is host specific, they have differed in interpretation of the strength of their findings regarding species cross-over and the need for canine scabies control to prevent human itch. Given that there is also indication from case reports that canine scabies leads to human itch, we propose that further investigation of the potential burden of zoonotic canine scabies and intervention trials of canine scabies prevention on the incidence of impetigo are warranted. Considering the devastating impacts of ARF and RHD, evidence is required to support policy to eliminate all risk factors.
Sujet(s)
Maladies des chiens , Rhumatisme cardiaque , Gale , Animaux , Gale/médecine vétérinaire , Gale/prévention et contrôle , Gale/épidémiologie , Chiens , Humains , Maladies des chiens/prévention et contrôle , Maladies des chiens/parasitologie , Maladies des chiens/épidémiologie , Rhumatisme cardiaque/prévention et contrôle , Rhumatisme cardiaque/épidémiologie , Australie/épidémiologie , Zoonoses/prévention et contrôle , Impétigo/microbiologie , Impétigo/prévention et contrôle , Streptococcus pyogenes , Infections à streptocoques/médecine vétérinaire , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/épidémiologie , Infections à streptocoques/microbiologie , Facteurs de risque , Rhumatisme articulaire aigu/prévention et contrôleRÉSUMÉ
BACKGROUND: The involvement of pregnant women in vaccine clinical trials presents unique challenges for the informed consent process. We explored the expectations and experiences of the pregnant women, spouses/partners, health workers and stakeholders of the consent process during a Group B Streptococcus maternal vaccine trial. METHODS: We interviewed 56 participants including pregnant women taking part in the trial, women not in the trial, health workers handling the trial procedures, spouses, and community stakeholders. We conducted 13 in-depth interviews and focus group discussions with 23 women in the trial, in-depth interviews with 5 spouses, and 5 women not in the trial, key informant interviews with 5 health workers and 5 other stakeholders were undertaken. RESULTS: Decision-making by a pregnant woman to join a trial was done in consultation with spouse, parents, siblings, or trusted health workers. Written study information was appreciated by all but they suggested the use of audio and visual presentation to enhance understanding. Women stressed the need to ensure that their male partners received study information before their pregnant partners joined a clinical trial. Confidentiality in research was emphasised differently by individual participants; while some emphasised it for self, others were keen to protect their family members from being exposed, for allowing them to be involved in research. However, others wanted their community participation to be acknowledged. CONCLUSION: We found that pregnant women make decisions to join a clinical trial after consulting with close family. Our findings suggest the need for an information strategy which informs not only the pregnant woman, but also her family about the research she is invited to engage in.
Sujet(s)
Allaitement naturel , Prise de décision , Consentement libre et éclairé , Femmes enceintes , Recherche qualitative , Humains , Femelle , Grossesse , Ouganda , Consentement libre et éclairé/éthique , Adulte , Femmes enceintes/psychologie , Mâle , Conjoints , Groupes de discussion , Essais cliniques comme sujet/éthique , Infections à streptocoques/prévention et contrôle , Confidentialité , Personnes se prêtant à la recherche/psychologie , Jeune adulte , Personnel de santé/psychologie , Streptococcus agalactiaeRÉSUMÉ
OBJECTIVE: Tetracycline and macrolide resistance are frequently linked in streptococci and other species. We aimed to assess the association between doxycycline use and azithromycin MICs in oral streptococci. METHODS: Linear regression was used to assess the association between doxycycline use in the prior year and the median MIC per participant of oral streptococcal colonies isolated at the baseline visit of the ResistAZM study. The analysis controlled for receipt of other antimicrobials as well as time since antimicrobial consumption. RESULTS: Fifty-six individual colonies confirmed to be streptococci were isolated from 19 individuals at baseline. The azithromycin MICs of these isolates varied considerably between 0.25 mg/L and >256 mg/L (median 28 mg/L; IQR 1-192 mg/L). The consumption of doxycycline in the preceding 12 months was positively associated with median streptococcal azithromycin MIC (coef. 151.6 [95% CI 10.6-292.7]; p = .037). CONCLUSION: This post-hoc analysis found that doxycycline use was associated with streptococcal azithromycin susceptibility. Numerous limitations of the study design mean that this study is best considered hypothesis generating. Prospective studies are required to assess if the use of doxycycline could select for macrolide resistance in oral streptococci.
Sujet(s)
Antibactériens , Azithromycine , Doxycycline , Résistance bactérienne aux médicaments , Tests de sensibilité microbienne , Infections à streptocoques , Streptococcus , Humains , Azithromycine/pharmacologie , Doxycycline/usage thérapeutique , Antibactériens/pharmacologie , Mâle , Femelle , Adulte , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/microbiologie , Infections à streptocoques/traitement médicamenteux , Streptococcus/effets des médicaments et des substances chimiques , Streptococcus/isolement et purification , Adulte d'âge moyen , Bouche/microbiologieRÉSUMÉ
AIM: To compare the prophylactic efficacy of ampicillin and clindamycin against vertical transmission of group B Streptococcus from mothers to their infants by evaluating the rates of group B Streptococcus colonisation. METHODS: We retrospectively extracted data for mothers who delivered at Showa University Northern Yokohama Hospital between 1 October 2017 and 31 March 2021 and tested positive for antepartum group B Streptococcus, and their infants. The chi-square test was used to compare the rates of group B Streptococcus colonisation, sepsis, and meningitis. We conducted a multivariate logistic regression analysis, including the time interval between membrane rupture and delivery, chorioamnionitis, and maternal intrapartum fever (≥38.0°C). RESULTS: Two hundred fifty-nine mothers and their infants were eligible. Ampicillin and clindamycin were administered to 150 and 109 mothers, respectively. In the ampicillin and clindamycin groups, 12.0% (18/150) and 37.6% (41/109) infants were group B Streptococcus positive, respectively. The rate of group B Streptococcus colonisation among infants was significantly lower in the ampicillin group (p < 0.001). Multivariate regression analysis showed similar results (p < 0.001). No sepsis or meningitis cases were observed in either group. CONCLUSION: Prophylactic efficacy of clindamycin against the vertical transmission of group B Streptococcus is lower than that of ampicillin.